Wedbush lowered the firm's price target on Larimar Therapeutics to $12 from $13 and keeps an Outperform rating on the shares. Most notable in the update, Larimar remains on track to start its rolling BLA submission for nomlabofusp in Q2 2026, the firm notes. Completion of all modules will wrap in the second half of 2026 as the CMC section concludes. Assuming submission by September, Wedbush still sees potential for a Q2 2027 U.S. launch.
